November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Regina Barragan-Carrillo: Rana McKay is an absolute force in oncology
Nov 10, 2024, 14:06

Regina Barragan-Carrillo: Rana McKay is an absolute force in oncology

Regina Barragan-Carrillo, postdoctoral fellow at the Genitourinary Clinic at the Medical Oncology and Medical Therapeutics at City of Hope, shared a post by Rana McKay, Associate Professor of Medicine at UC San Diego, on X, adding:

“Rana McKay is an absolute force in oncology! Her unwavering commitment to advancing educational initiatives for patients, along with her eagerness to mentor and uplift colleagues from around the world, is nothing short of inspiring.

She is the perfect candidate for the ASCO Nominating Committee—dedicated, visionary, and always willing to go the extra mile. Let’s show our support!

Cast your vote here.”

Quoting Rana McKay‘s post:

“Love this lady! Regina Barragan-Carrillo came to UC San Diego Health Moores Cancer Center to help plan video to enhance clinical trial enrollment.”

Regina Barragan-Carrillo

More posts featuring Regina Barragan-Carrillo and Rana McKay on oncodaily.com

Rana McKay – Candidate for ASCO Nominating Committee

Dr. Rana McKay is a board-certified medical oncologist and specializes in urogenital cancers, offering treatment for bladder, kidney, prostate, and testicular cancer patients. Leading a multi-disciplinary prostate cancer clinic at UC San Diego, she ensures comprehensive care through collaboration with urologists and radiation oncologists.

As an associate professor, Dr. McKay mentors students and conducts research on clinical trials and novel biomarkers for genitourinary malignancies. Dr. McKay is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.

Regina Barragán Carrillo, MD, is a postdoctoral fellow at City of Hope’s Genitourinary Clinic, specializing in Medical Oncology and Therapeutics in Duarte, California. Her work focuses on prostate and kidney cancers, with an interest in improving patient communication and outcomes.